Surface receptor expression patterns associated with adaptive NK cells in patients with GATA2 mutation. PBMCs from CMV-seronegative (n = 12) and -seropositive (n = 26) healthy donors as well as patients (n = 10) and asymptomatic carriers (n = 3) with heterozygous GATA2 mutations were examined by flow cytometry. Graphs depict the percentages of CD3⁻CD56^dim/CD16⁺ NK cells expressing (A) NKG2A, (B) CD85j, (C) high levels of CD7, (D) CD161, (E) CD2, (F) CD16, and (G) CD56. CMV serostatus for GATA2 patients and carriers is indicated as seronegative (open circles), seropositive (gray circles), or undetermined (black circles). Boxes indicate 25th, 50th (median), and 75th percentiles, with a plus indicating the mean. For box plots, whiskers indicate 95% confidence intervals. Otherwise, error bars indicate mean with SD. P values were determined using the Student unpaired t test. *P < .05, **P < .01, and ***P < .001. (H-I) Contour plots show CD56 and CD16 expression on CD3⁻ lymphocytes on representative CMV-seropositive healthy donors with adaptive NK-cell expansions as well as 2 selected patients with heterozygous GATA2 mutation and high frequencies of CD3⁻CD16⁺CD56⁻ NK cells. Plots gated on CD3⁻CD16⁺/CD56⁺ NK cells depict CD56 vs NKp46, FcεRγ, PLZF, CD57, NKG2A, T-bet, and Eomes expression.